News >

Pomalidomide Effective in Multiple Myeloma With Renal Impairment

Jason Harris
Published: Monday, Feb 19, 2018

Meletios Dimopoulos, MD

Meletios Dimopoulos, MD
Pomalidomide (Pomalyst) in combination with low-dose dexamethasone induced an overall response rate (ORR) of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment (RI), according to phase II study findings published in the Journal of Clinical Oncology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x